The rapid advancement of AI models in recent years has transformed the field of protein design, enabling the creation of de novo proteins with precisely defined structural and functional properties.

Company to focus on the rapid development of miniproteins tailor-made for therapeutics, driving down costs and shortening the time required to develop safer, more effective medicines.

Diffuse Bio, a leading provider of AI and experimental platforms for designing and screening protein therapeutics, today announced significant enhancements to DiffuseSandbox, its self-serve protein ...

Researchers from the lab of Nobel laureate, David Baker, PhD, have now released RFdiffusion3 open source. The latest version of the de novo protein design model generates proteins that interact with ...

(Nanowerk News) Reporting in Science ("De novo design of porphyrin-containing proteins as efficient and stereoselective catalysts"), researchers at UC Santa Barbara, UCSF and the University of ...

BOSTON--(BUSINESS WIRE)--AI Proteins, Inc., a biotechnology company that utilizes computational de novo protein design to create therapeutic miniproteins, announced today it has entered into a ...

Galux announced a $29 million Series B round—bringing total funding to $47 million—to accelerate its AI-driven protein therapeutics platform and growth. The Series B round brought together a group of ...

For the field of drug development, hitting the right target with atomic precision to achieve therapeutic effect remains the core challenge. While traditional R&D pipelines are dependent on ...